Physicians' Academy for Cardiovascular Education

Achieving optimal glycemic control: What are the current options in management?

3' education - Dec. 7, 2011

Prof. Bernard Charbonell (University of Nantes, France)
The lecture of dr. Charbonnel was about the current options to achieve optimal glycemic control. In summary, his advice about HbA1c is:
  • < 7% in patients < 60 years of age without any complications or comorbidities;
  • < 7.5% in frail patients.
The options are what is next on top of metformin, such as sulfonylureas, pioglitazone, GLP-1 agonists and finally insulin.
To reduce cardiovascular risk in diabetic patients is a critical question. The large outcome studies about HbA1c reduction have been “disappointing”, he tells.

Topics discussed in this PACE Talk:
  • What are the options for optimal glycemic control?
  • What are the disadvantages of sulfonylurea?
  • What are the pro’s and cons of glitazones?
  • How to reduce the cardiovascular risk in diabetic patients?
  • Outcomes of the 5 main studies for blood glucose lowering in type 2 diabetes
  • The benefit of early intensification on top of metformin 

About the speaker:
Professor Bernard Charbonnel is currently Professor of Endocrinology and Metabolic Diseases at the University of Nantes in France.
Professor Charbonnel is a former President of the French Diabetes Society and has held the position of Vice President of Research at the University of Nantes. He has also been Chair of the French Diabetes Guidelines Committee and is a member of several prestigious committees including the European Society for the Study of Diabetes.
Professor Charbonnel is a Principal National Investigator and International Coordinator for a number of multicentre clinical trials, and was a member of the executive committee of the PROactive Study.
Diabetes clinical research is Professor Charbonnel’s main field of interest. His research has focused on insulin therapy in type 1 and type 2 diabetes, prevention of cardiovascular complications in diabetes, emerging treatments, and ways to optimize diabetes management. Dr Charbonnel has published more than 300 original and review papers in these fields.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: